Overview

Millennium Biotechnologies Group, Inc. engages in the research, development, and marketing of specialized nutritional supplements as an adjunct to medical treatments for select medical conditions, as well as for individuals seeking improved recovery and advanced performance. The Company’s currently marketed products are targeted toward immuno-compromised individuals undergoing medical treatment for diseases, such as cancer†, as well as individuals living with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and wound healing and post-surgical healing, among other conditions.

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(R) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

---

Investment Highlights

---

Products

Resurgex Select®

Resurgex Select® is a whole foods-based nutritional product that is designed to be used throughout the course of cancer treatment (chemotherapy, radiation, etc.), as many times patients lose weight and cannot consume adequate nutrition. This product combines dietary fiber (3 g), low sugar (5 g), and high protein (15 g) with no added antioxidants to be a high-calorie (350 calorie) supplement. The omission of antioxidants is important because many oncologists prefer to avoid the risk that antioxidants may pose during their patient’s treatments. With this nutritional formula (which may be administered orally or fed through a gastrointestinal [GI] tube), the right balance of nutritional support can be provided in one drink. It is available in three flavors (Vanilla Bean, Chocolate Fudge, and Fruit Smoothie) and each can be mixed with water, milk, juices, or in soft cold foods such as yogurt, apple sauce, or pudding.

Resurgex Plus®

Resurgex Plus® is a high-protein (21 g), high-calorie (400 calorie), antioxidant-rich, enteral nutritional formula providing multiple comprehensive nutritional regimens into one drink. This product (which is available in Chocolate and Vanilla Cream) may serve as a meal replacement or as a sole source of nutrition when directed by a physician following a patient’s treatment. Concentrated calories are derived from high-quality food sources rather than corn oil, sucrose, and corn syrup, which are commonly found in more well-known nutritional supplements.

Resurgex®

Resurgex® is a high-protein (12 g), low-sugar (5 g), low-calorie (90 calorie), antioxidant-rich, nutritional formula, which may be administered orally or fed through a GI tube. This drink, which is available in two flavors (Vanilla Supreme and Fruit Blast), is commonly used as a nutritional supplement to meals and is intended to promote wellness. It can also be mixed with water, milk, juices, or in soft cold foods such as yogurt, apple sauce, or pudding.

Resurgex® Fusion

While Resurgex® and Resurgex Plus® are the first multi-component nutritional supplements to address the various dietary needs of immuno-compromised individuals, Millennium also has (in development) Resurgex® Fusion, a nutritional support formula that aims to address the concerns of many elite athletes who suffer from like symptoms (fatigue, lean muscle loss, lactic acid buildup, oxidative stress, and stressed immune systems). This formula includes many of the benefits of the Resurgex® products and is designed to improve recovery parameters in efforts to enhance the performance of professional and collegiate athletes.

While Resurgex® or Resurgex Plus® can be effective when taken by athletes, the National Collegiate Athletic Association (NCAA) has specific rules about the use of certain amino acids, or anabolic agents. In fact, colleges and universities are prohibited from purchasing any product that contains amino acids or anabolic agents for athletes. This led to the development of the Company’s Resurgex® Fusion nutritional support formula.

The Company’s products are unique in that they deliver healthy, whole food calories and do not contain high-fructose corn syrup or corn oil, which are not healthy or suitable forms of calories for Millennium’s targeted markets. These ingredients have also shown to correlate with an increase in obesity, a promotion of insulin resistance, and are implicated in inflammation and cancer. Additionally, the use of high levels of Omega-6 fats (corn oil) has been shown to promote tumor growth in animal models. In contrast, Millennium’s nutritional products deliver 15 nutraceutical ingredients that specifically address the needs of chronically ill patients.

Millennium has chosen to focus its current product marketing efforts toward the medical community, vis-à-vis a pharmaceutical sales approach and distribution model, as the Company believes that this approach provides credibility and legitimacy that competitive brands (which largely target the mass markets) may lack. Upon reaching the market with its sports nutritional formula, the Company expects to form distribution agreements with professional and amateur athletic organizations.

---

Growth Strategy & Distribution

Millennium has implemented a variety of strategies and formed partnerships that are intended to penetrate the various specialized markets for nutritional products, which are targeted by the Company (oncology patients, immuno-compromised individuals, and athletes seeking effective sports recovery). Currently, products can be purchased through the Company’s websites, www.milbiotech.com and www.resurgex.com, soon through the website www.caring4cancer.com, or ordered by phone (877) RESURGX. Additionally, in select areas, Medicaid-associated pharmacies distribute the Company’s products. Furthermore, select international distribution agreements are in place, which are intended to expand the Company beyond U.S. markets.

Various recognized authorities, such as the Mayo Clinic (www.mayoclinic.com), the National Institutes of Health (NIH), and the Johns Hopkins Hospital and Health System agree that nutritional supplements could offer benefits to patients affected by cancer and other immuno-compromised conditions, whose required nutritional demands exceed their current intake. However, many of the well-known and market-leading nutritional supplements, such as Boost® by Novartis AG (NVS-NYSE), Ensure® by the Ross Product Division of Abbott Laboratories Inc. (ABT-NYSE), Carnation® Instant Breakfast® by Nestlé S.A. (NESN-VTX), and various generic products, contain high amounts of high-fructose corn syrup and corn oil, and provide low-quality protein, carbohydrates, and fats.

Many cancer patients have metabolic problems, which include insulin resistance and hyperglycemia, which makes the use of high-fructose corn syrup even more dangerous to a patient. Hyperinsulinemia and hyperglycemia are adverse prognostic factors that increase risk of distant metastases and shorten survival. Additionally, diets high in simple sugars have demonstrated to increase the risk of many types of cancer, cause an increased increment in plasma glucose comparable to sucrose, and increase insulin resistance.

PRODUCT DISTRIBUTION

Oncology Market Distribution

P4 Healthcare, LLC

Millennium and P4 Healthcare, LLC formed a strategic alliance in May 2007 to deliver the Resurgex® line of nutritional products to cancer patients and oncology practices. The partnership brings Millennium together with P4 Healthcare, a leading worldwide provider of customized solutions for oncology practices featuring premier patient educational resources and practice management tools.

Through its website, www.caring4cancer.com, and its own patient guide, Caring4Cancer, P4 Healthcare reaches more than 1.2 million cancer patients annually. Additionally, many of the nation’s largest oncology practices now use the Caring4Cancer patient guide, a quarterly publication serving the interests and needs of cancer patients, survivors, and their families, as their primary patient education tool.

Canadian Distribution

In March 2007, Millennium signed a Letter of Intent with a Canadian subsidiary of an international pharmaceutical company on terms for the distribution and marketing of the Resurgex® product line for the Canadian oncology market. Under the terms of reference, a distribution agreement may be formalized where Millennium may grant exclusive marketing rights to this pharmaceutical company to distribute and market its line of Resurgex® products for cancer patients in Canada. Being run as a pilot program, this program has the potential to expand into other areas of the world.

Greek Distribution

In April 2007, the Company entered into an international distribution partnership with Nutrimedica, a Greek distributor of nutritional products with knowledge of the local market and regulations in Greece. Under this agreement, Nutrimedica is to import and distribute the Resurgex® products to hospitals, pharmacies, and directly to patients. Nutrimedica has initiated introduction of the Resurgex® products to the market, and sales have steadily increased over the past year.

Filipino Distribution

In April 2007, Millennium signed a Letter of Intent to enter into a distribution agreement with New Marketlink Pharmaceutical Corp., a Philippine pharmaceutical company, for the distribution and marketing of the Resurgex® product line for the oncology market. Under the terms of the Letter of Intent, a distribution agreement may be formalized where Millennium could grant exclusive marketing rights to New Marketlink Pharmaceutical Corp. to distribute and market its line of Resurgex® products for cancer patients in the Philippines. Following the Filipino launch, distribution is expected to expand to Korea, Malaysia, Singapore, Thailand, Vietnam, Taiwan, and Indonesia.

Sports Nutrition Market Product Distribution

In order to penetrate the sports nutrition market, the Company expects to directly target the strength/conditioning coaches of professional sports teams. During the National Basketball Association (NBA) 2006-2007 season, there were several NBA organizations that purchased Resurgex® and or Resurgex® Plus and had players using the products before and after practices and games. Importantly, since many of the NBA coaches have come from the NCAA, many coaches at the collegiate level are aware of the Resurgex® line of products. However, due to NCAA rules of fairness, no university may offer or distribute supplements containing amino acids or anabolic agents to its athletes. For that reason, Millennium has developed an NCAA-compliant Resurgex® Fusion sports nutrition formula, devoid of amino acids or anabolic agents, which is fully compliant with the NCAA rules and could therefore be used by universities. In addition, each batch of Resurgex® Fusion is certified by the BSCG to not contain any banned substances.

Other Distributors - Medicare/Medicaid

Millennium has received federal government approval to have its nutritional products covered by Medicare. After receiving Medicare approval by the federal government, Millennium started lobbying state governments for Medicaid approval, which would allow the Company to have its products distributed or retailed in HIV clinics, oncology centers, and pharmacies throughout each state. Currently, Millennium has received Medicaid and Medicare approval for the Resurgex® line of products in the following states: Connecticut, Florida, Michigan, Nevada, New Jersey, New York, and Pennsylvania.

---

Medical Institutions Prescribing Resurgex

Many hospitals and pharmacies already prescribe Millennium’s products for support during oncology treatments or for recovery. A listing of some of these medical institutions is provided below:.

Product Distribution in Infectious Disease Markets

The hospitals currently dispensing Millennium’s products through their infectious disease outpatient clinics are listed below:

---

Resurgex® Metabolic/Virological: Quality of Life Study

A six-month study of 26 HIV-1-infected patients on HAART was conducted at the Center for Family Health at the University of Medicine and Dentistry of New Jersey (UMDNJ)/St. Mary’s Hospital (Hoboken, New Jersey). In the study, patients were given Resurgex® twice daily. A standardized quality of life questionnaire, approved by the Investigational Review Board (IRB), was completed at baseline and follow-up visits. The results of this questionnaire are summarized in the chart below:

---

Recent & Potential Milestones

Recent Milestones

• Millennium has recently entered into an agreement with P4 Healthcare, LLC to provide large, private oncology practices with a means of offering the Resurgex® Continuum of Care to their patients. The partnership brings together Millennium with P4 Healthcare, one of the leading providers of customized solutions for oncology practices featuring patient educational resources and practice management tools. Through its website, www.caring4cancer.com, and patient guide, Caring4Cancer, more than 1.2 million cancer patients are reached annually. Many of the nation’s largest oncology practices now use the Caring4Cancer patient guide, a quarterly publication serving the interests and needs of cancer patients, survivors, and their families, as their primary patient education tool. With coverage of all aspects of cancer care—from diagnosis and treatment to side effect management, nutrition, finances, sexuality, spirituality, and lifestyle matters—Caring4Cancer has become a key patient education resource prescribed by doctors and nurses just as they prescribe medication or therapy.
• Millennium conducted two double-blind placebo-controlled clinical trials for its sports nutritional formula at Rutgers University among the Men’s Division I Soccer and Football teams. These studies demonstrated the product’s beneficial effects as post-workout recovery aid versus placebo, assisting the athlete in maximizing training responses and assisting in optimal recovery.
• Millennium recently created (not yet on the market) a compliment to the Resurgex® Continuum of Care in the form of confectionary bars and freeze pops. These newly developed line extensions are expected to provide the same quality nutrition as the beverages. The freeze pops could become an attractive option for head and neck cancer patients who have difficultly or are incapable of swallowing, whereas the bars may become a more attractive option for athletes.
• Received AIDS Drug Assistance Program (ADAP) approval in New York.
• Received Special Pharmaceutical Benefits Program approval in Pennsylvania.
• Resurgex® has been dispensed in over 315 different pharmacies in seven different states.
• Resurgex® is available through large national and regional pharmaceutical wholesalers, including Kinray Inc., Cardinal Health Inc. (CAH-NYSE), Amerisource-Bergen Corp. (ABC-NYSE), McKesson Corp. (MCK-NYSE), Bellco Health Corp., and Rochester Drug.
• Resurgex® is now being prescribed in many prestigious medical institutions nationwide.

Potential Milestones

• Millennium is expected to launch its Resurgex® Fusion sports nutrition formula into the market by the end of 2007.
• The Company is in the process of developing a formula to address the tube-feeding market and has targeted to enter this market by the first quarter 2008.
• Millennium is expected to bring to market its confectionary bars and freeze pops, which could provide the same quality and benefit as the beverages.
• The Company is expected to enter into additional distribution agreements.

Recent News and Press Releases

MILLENNIUM BIOTECHNOLOGIES GROUP INC Financials (Fri, Dec 14)

MILLENNIUM BIOTECHNOLOGIES GROUP INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements (Fri, Dec 7)

Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order (Thu, Dec 6)

Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets (Mon, Nov 26)

MILLENNIUM BIOTECHNOLOGIES GROUP INC Files SEC form 10QSB, Quarterly Report (Mon, Nov 19)

Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio (Tue, Nov 13)

MILLENNIUM BIOTECHNOLOGIES GROUP INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme (Tue, Sep 11)

MILLENNIUM BIOTECHNOLOGIES GROUP INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements (Fri, Sep 7)

MILLENNIUM BIOTECHNOLOGIES GROUP INC Files SEC form 10QSB, Quarterly Report (Mon, Aug 20)

---

Management

Jerry E. Swon, President, Chief Executive Officer, and Chairman

Mr. Jerry E. Swon, a founder of Millennium, has been the Company’s president and chief executive officer (CEO) since its formation, and its president, CEO, and chairman of the Board since July 2001. Prior to joining Millennium, and since 1992, he was the CEO of Royal Capital Inc., a New Jersey-based company that provided financial consulting and corporate structuring services to private and public companies. In 1998, Mr. Swon served as CEO and as a director of Magnitude Information Systems Inc., a company engaged in the design and development of ergonomic software for office uses. He was also co-founder of the Tax Transfer Corporation of New Jersey in 1999. Mr. Swon received a B.A. from Hamline University in 1972.

Frank Guarino, Chief Financial Officer

Mr. Frank Guarino has been Millennium’s chief financial officer (CFO) since October 2001. He was previously employed from December 1997 through February 2001 as the controller with First National Funding Corporation of America, a mortgage banking firm with 55 branches nationwide producing over $350 million in annual volume at the time of his departure. Mr. Guarino earned a B.S. in accounting from St. Peter’s College in 1997.

Carl Germano, Executive Vice President, Research and Product Development

Mr. Carl Germano serves as Millennium’s executive vice president of research and product development. He is a registered, certified, and licensed nutritionist. Mr. Germano holds a Master’s degree in clinical nutrition from New York University and has over 27 years of experience using innovative, complementary nutritional therapies in private practice. For the past 20 years, he has dedicated his efforts to research and product development for the dietary supplement and medical foods industries, where he has been instrumental in bringing unique nutritional substances and formulations to the health/dietary supplement industry. From April 1999 to July 2001, Mr. Germano was senior vice president of research and product development with Nutratech, Inc., a nutraceutical raw materials supplier. From 1992 to 1999, he was vice president of product development and research with Solgar Vitamin and Herb (noting that in 2005 NBTY Inc. [NTY-NYSE] purchased the Solgar Vitamin and Herb Co. from Wyeth Consumer Healthcare [WYE-NYSE]).
 

---

Contacts

Millennium Biotechnologies, Inc.
665 Martinsville Road, Suite 219
Basking Ridge, New Jersey 07920

Phone: (908) 604-2500
Toll Free: (888) 412-9179
Order : 1-877-RESURGX (737-8749)
Fax: (908) 604-2545

email: info@milbiotech.com

---

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect Millennium Biotechnologies, Inc. current expectations about its future results, performance, prospects and opportunities. Millennium Biotechnologies, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Millennium Biotechnologies, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Millennium Biotechnologies, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2008 AllPennyStocks.com Media, Inc. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated sixteen thousand dollars by a non-affiliated third-party, Shah and Associates LLC. for its efforts in presenting the MBTG profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.